About argenx se - ARGX
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
ARGX At a Glance
argenx SE
Laarderhoogtweg 25
Amsterdam, Noord-Holland 1101 EB
| Phone | 31-76-303-04-88 | Revenue | 4.17B | |
| Industry | Biotechnology | Net Income | 1.30B | |
| Sector | Health Technology | 2025 Sales Growth | 90.56% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,863 | |
| View SEC Filings |
ARGX Valuation
| P/E Current | 35.302 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 39.772 |
| Price to Sales Ratio | 13.328 |
| Price to Book Ratio | 7.106 |
| Price to Cash Flow Ratio | 65.29 |
| Enterprise Value to EBITDA | 50.036 |
| Enterprise Value to Sales | 12.273 |
| Total Debt to Enterprise Value | 0.001 |
ARGX Efficiency
| Revenue/Employee | 2,236,357.336 |
| Income Per Employee | 695,669.79 |
| Receivables Turnover | 2.514 |
| Total Asset Turnover | 0.56 |
ARGX Liquidity
| Current Ratio | 5.226 |
| Quick Ratio | 4.867 |
| Cash Ratio | 3.363 |
ARGX Profitability
| Gross Margin | 88.673 |
| Operating Margin | 23.852 |
| Pretax Margin | 29.577 |
| Net Margin | 31.107 |
| Return on Assets | 17.414 |
| Return on Equity | 20.217 |
| Return on Total Capital | 17.585 |
| Return on Invested Capital | 20.109 |
ARGX Capital Structure
| Total Debt to Total Equity | 0.644 |
| Total Debt to Total Capital | 0.64 |
| Total Debt to Total Assets | 0.543 |
| Long-Term Debt to Equity | 0.496 |
| Long-Term Debt to Total Capital | 0.493 |